Severity
Moderate
FDA Drug recall · Reported July 30, 2025
Sub-Potent Drug: Subpotent assay results during stability testing.
Imprimis Njof, LLC recalled Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Im… - a moderate-severity action.
Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Im… was recalled by Imprimis Njof, LLC in July 30, 2025. Reason: Sub-Potent Drug: Subpotent assay results during stability testing.. Check the official notice for the remedy. Verify recall #D-0535-2025 with the FDA Drug before acting.
The recall
Imprimis Njof, LLC issued this moderate-severity FDA Drug recall-Sub-Potent Drug: Subpotent assay results during stability testing..
Sourced from official FDA Drug enforcement records. Verify recall #D-0535-2025 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0535-2025) was formally reported on July 30, 2025, with the manufacturer initiating the action on July 9, 2025. It is classified under Moderate severity (Class II), with a current status of Completed. Imprimis Njof, LLC is listed as the recalling firm, operating out of Ledgewood, NJ. Federal records list the affected scope as 6,880 vials.
The documented reason for this recall is: Sub-Potent Drug: Subpotent assay results during stability testing. Distribution data in the federal record shows the product reached: Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
6,880 vials
Related Recalls
6
5 from same agency
Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Imprimis NJOF, 1705 Route 46 West, Unit 6B Ledgewood, NJ, 07852 NDC: 71384-641-01
Sub-Potent Drug: Subpotent assay results during stability testing.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Completed |
| Recall number | D-0535-2025 |
| Date reported | July 30, 2025 |
| Date initiated | July 9, 2025 |
| Recalling firm | Imprimis Njof, LLC |
| Firm location | Ledgewood, NJ |
| Affected scope | 6,880 vials |
| Distribution | Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 30, 2025. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.